Avaliação de polimorfismos dos genes CYP1A1 e CYP2E1 no risco para cirrose hepática e carcinoma hepatocelular
Autor(a) principal: | |
---|---|
Data de Publicação: | 2017 |
Tipo de documento: | Dissertação |
Idioma: | por |
Título da fonte: | Biblioteca Digital de Teses e Dissertações da FAMERP |
Texto Completo: | http://bdtd.famerp.br/handle/tede/472 |
Resumo: | Liver cancer ranks fifth in incidence and third in mortality worldwide. Most new cases and deaths occur in developing countries. Cirrhosis is a major risk factor for hepatocellular carcinoma (HCC). Several studies have shown that polymorphisms in cytochrome P450 (CYPs) genes can contribute to the etiology of complex diseases, as well as liver cancer. Polymorphisms in the genes of this family can alter the expression or function of the protein and influence the individual levels of detoxification, which contribute to the development of liver diseases. Objective: To investigate the association between the genetic polymorphisms CYP1A1*2A (rs4646903), CYP1A1*2C (rs1048943), CYP2E1*5B (rs2031920), CYP1E1*6 (rs6413432) and the risk of hepatic cirrhosis and HCC. Casuistic and Methods: Seven hundred and forty-five subjects (160 cirrhosis patients, 97 HCC patients and 488 controls) were evaluated. Polymorphisms were investigated by polymerase chain reaction / restriction fragment length polymorphism (PCR-RFLP) and Real-Time PCR. Statistical analyses were performed by chi-square and binary logistic regression. Survival analysis was performed using Kaplan Meier curve and Log rank test. Results: The results showed that age ≥ 60 years was associated with HCC (OR = 12.22, 95% CI: 7.17-20.82, p <0.001) and age ≥57 years was a risk factor for cirrhosis (OR = 7.12 CI 95% 4.68-10.84, p <0.001). Hepatitis B (OR = 7.84, 95% CI: 1.86-33.08, p = 0.005) and alpha fetoprotein> 500 ng / mL (OR = 3.73, 95% CI: 1.25-11, 13; p = 0.018) were associated with HCC. The polymorphisms CYP1A1 *2A, CYP1A1 *2C, CYP2E1 *5B and CYP2E1 *6 were not associated with risk of HCC and cirrhosis (p> 0.05), as well as CYP1A1 and CYP2E1 haplotypes (p > 0.05). There was no interaction between polymorphisms and smoking or alcohol consumption in the risk for HCC and cirrhosis (p> 0.05). No association was found between the polymorphisms and clinical parameters in HCC patients (p> 0.05). CYP2E1 *5B and CYP2E1 *6 polymorphisms were associated with a reduction in survival in HCC patients (p = 0.0234 and p = 0.0424, respectively). Conclusion: This study concludes that age is associated with the risk of developing HCC and cirrhosis, and CYP2E1 *5B and CYP2E1 *6 polymorphisms contribute for the reduced survival in HCC patients. |
id |
FMRP_0e9974823ea353732eb7309502df07f4 |
---|---|
oai_identifier_str |
oai:localhost:tede/472 |
network_acronym_str |
FMRP |
network_name_str |
Biblioteca Digital de Teses e Dissertações da FAMERP |
repository_id_str |
4711 |
spelling |
Goloni-Bertollo, Eny Mariahttp://lattes.cnpq.br/9176636696202692Castanhole-Nunes, Márcia Maria Urbaninhttp://lattes.cnpq.br/0665944455231316Cintra, Mariangela Torreglosa Ruizhttp://lattes.cnpq.br/542081997039984835409856899http://lattes.cnpq.br/2023219167678846Agren, Camila2018-11-12T17:44:43Z2017-10-20Agren, Camila. Avaliação de polimorfismos dos genes CYP1A1 e CYP2E1 no risco para cirrose hepática e carcinoma hepatocelular. 2017. 107 f. Dissertação (Programa de Pós-Graduação em Ciências da Saúde) - Faculdade de Medicina de São José do Rio Preto, São José do Rio Preto.1334http://bdtd.famerp.br/handle/tede/472Liver cancer ranks fifth in incidence and third in mortality worldwide. Most new cases and deaths occur in developing countries. Cirrhosis is a major risk factor for hepatocellular carcinoma (HCC). Several studies have shown that polymorphisms in cytochrome P450 (CYPs) genes can contribute to the etiology of complex diseases, as well as liver cancer. Polymorphisms in the genes of this family can alter the expression or function of the protein and influence the individual levels of detoxification, which contribute to the development of liver diseases. Objective: To investigate the association between the genetic polymorphisms CYP1A1*2A (rs4646903), CYP1A1*2C (rs1048943), CYP2E1*5B (rs2031920), CYP1E1*6 (rs6413432) and the risk of hepatic cirrhosis and HCC. Casuistic and Methods: Seven hundred and forty-five subjects (160 cirrhosis patients, 97 HCC patients and 488 controls) were evaluated. Polymorphisms were investigated by polymerase chain reaction / restriction fragment length polymorphism (PCR-RFLP) and Real-Time PCR. Statistical analyses were performed by chi-square and binary logistic regression. Survival analysis was performed using Kaplan Meier curve and Log rank test. Results: The results showed that age ≥ 60 years was associated with HCC (OR = 12.22, 95% CI: 7.17-20.82, p <0.001) and age ≥57 years was a risk factor for cirrhosis (OR = 7.12 CI 95% 4.68-10.84, p <0.001). Hepatitis B (OR = 7.84, 95% CI: 1.86-33.08, p = 0.005) and alpha fetoprotein> 500 ng / mL (OR = 3.73, 95% CI: 1.25-11, 13; p = 0.018) were associated with HCC. The polymorphisms CYP1A1 *2A, CYP1A1 *2C, CYP2E1 *5B and CYP2E1 *6 were not associated with risk of HCC and cirrhosis (p> 0.05), as well as CYP1A1 and CYP2E1 haplotypes (p > 0.05). There was no interaction between polymorphisms and smoking or alcohol consumption in the risk for HCC and cirrhosis (p> 0.05). No association was found between the polymorphisms and clinical parameters in HCC patients (p> 0.05). CYP2E1 *5B and CYP2E1 *6 polymorphisms were associated with a reduction in survival in HCC patients (p = 0.0234 and p = 0.0424, respectively). Conclusion: This study concludes that age is associated with the risk of developing HCC and cirrhosis, and CYP2E1 *5B and CYP2E1 *6 polymorphisms contribute for the reduced survival in HCC patients.O câncer de fígado ocupa o quinto lugar em incidência e o terceiro em mortalidade em todo o mundo. A maioria dos novos casos e mortes ocorre em países em desenvolvimento. A cirrose é um dos principais fatores de risco para o desenvolvimento de carcinoma hepatocelular (CHC). Vários estudos demonstram que polimorfismos nos genes Citocromo P450 (CYPs) podem contribuir para a etiologia de doenças complexas, assim como o câncer de fígado. Os polimorfismos nos genes desta família podem alterar a expressão ou a função da proteína e influenciar os níveis individuais de detoxificação que contribuem para o desenvolvimento de doenças hepáticas. Objetivo: Investigar a associação dos polimorfismos CYP1A1*2A (rs4646903), CYP1A1*2C (rs1048943), CYP2E1*5B (rs2031920 e CYP1E1*6 (rs6413432) e o risco para cirrose e CHC. Casuística e métodos: Foram avaliados 745 indivíduos (160 pacientes com cirrose, 97 com CHC e 488 controles). Os polimorfismos foram investigados por Reação em Cadeia da Polimerase / Polimorfismo de Comprimento de Fragmento de Restrição (PCR-RFLP) e PCR em Tempo Real. As análises estatísticas foram realizadas por Qui-quadrado, Regressão logística binária. A análise de sobrevida foi realizada utilizando a Curva de Kaplan Meier e o teste Log-rank. Resultados: Os resultados mostraram que a idade ≥ 60 anos foi associada com CHC (OR = 12,22; IC 95%: 7,17-20,82; p <0,001) e idade ≥ 57 anos foi um fator de risco para cirrose (OR = 7,12 IC 95% 4,68-10,84; p < 001). Hepatite B (OR = 7,84; IC 95%: 1,86-33,08; p = 0,005) e alfa fetoproteína > 500 ng / mL (OR = 3,73; IC 95%: 1,25-11,13; p = 0,018) foram associadas com CHC. Os polimorfismos CYP1A1 *2A, CYP1A1 *2C, CYP2E1 *5B e CYP2E1 *6 não foram associados ao risco de CHC e cirrose (p> 0,05), assim como os haplótipos CYP1A1 e CYP2E1 (P> 0,05). Não houve interação entre os polimorfismos e o consumo de tabaco ou álcool no risco para CHC e cirrose (p> 0,05). Não foi observada associação entre os polimorfismos e parâmetros clínicos em pacientes com CHC (p> 0,05). Os polimorfismos CYP2E1 *5B e CYP2E1 *6 foram associados com redução da sobrevida em pacientes com CHC (p = 0,0234 e p = 0,0424, respectivamente). Conclusão: Este estudo conclui que a idade está associada ao risco de desenvolver CHC e cirrose e os polimorfismos CYP2E1 *5B e CYP2E1 *6 contribuem para a redução da sobrevida em pacientes com CHC.Submitted by Suzana Dias (suzana.dias@famerp.br) on 2018-11-12T17:44:43Z No. of bitstreams: 1 CamilaAgren_dissert.pdf: 1055624 bytes, checksum: b3b1d5227ab027ab3f0ff1f941091471 (MD5)Made available in DSpace on 2018-11-12T17:44:43Z (GMT). No. of bitstreams: 1 CamilaAgren_dissert.pdf: 1055624 bytes, checksum: b3b1d5227ab027ab3f0ff1f941091471 (MD5) Previous issue date: 2017-10-20Coordenação de Aperfeiçoamento de Pessoal de Nível Superior - CAPES::2075167498588264571::600application/pdfporFaculdade de Medicina de São José do Rio PretoPrograma de Pós-Graduação em Ciências da Saúde::-6954410853678806574::500FAMERPBrasilFaculdade 1::Departamento 1::306626487509624506::500Polymorphism, GeneticLiver CirrhosisCarcinoma, HepatocellularPolimorfismo GenéticoCirrose HepáticaCarcinoma HepatocelularCIENCIAS DA SAUDE::8765449414823306929::600Avaliação de polimorfismos dos genes CYP1A1 e CYP2E1 no risco para cirrose hepática e carcinoma hepatocelularinfo:eu-repo/semantics/publishedVersioninfo:eu-repo/semantics/masterThesisinfo:eu-repo/semantics/openAccessreponame:Biblioteca Digital de Teses e Dissertações da FAMERPinstname:Faculdade de Medicina de São José do Rio Preto (FAMERP)instacron:FAMERPLICENSElicense.txtlicense.txttext/plain; charset=utf-82165bd3efa91386c1718a7f26a329fdcb468MD51ORIGINALCamilaAgren_dissert.pdfCamilaAgren_dissert.pdfapplication/pdf1055624b3b1d5227ab027ab3f0ff1f941091471MD52http://bdtd.famerp.br/bitstream/tede/472/1/license.txthttp://bdtd.famerp.br/bitstream/tede/472/2/CamilaAgren_dissert.pdftede/4722019-02-04 11:06:09.991oai:localhost: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Biblioteca Digital de Teses e Dissertaçõeshttp://bdtd.famerp.br/PUBhttps://bdtd.famerp.br/oai/requestsbdc@famerp.br||joao.junior@famerp.bropendoar:47112019-02-04T13:06:09Biblioteca Digital de Teses e Dissertações da FAMERP - Faculdade de Medicina de São José do Rio Preto (FAMERP)false |
dc.title.por.fl_str_mv |
Avaliação de polimorfismos dos genes CYP1A1 e CYP2E1 no risco para cirrose hepática e carcinoma hepatocelular |
title |
Avaliação de polimorfismos dos genes CYP1A1 e CYP2E1 no risco para cirrose hepática e carcinoma hepatocelular |
spellingShingle |
Avaliação de polimorfismos dos genes CYP1A1 e CYP2E1 no risco para cirrose hepática e carcinoma hepatocelular Agren, Camila Polymorphism, Genetic Liver Cirrhosis Carcinoma, Hepatocellular Polimorfismo Genético Cirrose Hepática Carcinoma Hepatocelular CIENCIAS DA SAUDE::8765449414823306929::600 |
title_short |
Avaliação de polimorfismos dos genes CYP1A1 e CYP2E1 no risco para cirrose hepática e carcinoma hepatocelular |
title_full |
Avaliação de polimorfismos dos genes CYP1A1 e CYP2E1 no risco para cirrose hepática e carcinoma hepatocelular |
title_fullStr |
Avaliação de polimorfismos dos genes CYP1A1 e CYP2E1 no risco para cirrose hepática e carcinoma hepatocelular |
title_full_unstemmed |
Avaliação de polimorfismos dos genes CYP1A1 e CYP2E1 no risco para cirrose hepática e carcinoma hepatocelular |
title_sort |
Avaliação de polimorfismos dos genes CYP1A1 e CYP2E1 no risco para cirrose hepática e carcinoma hepatocelular |
author |
Agren, Camila |
author_facet |
Agren, Camila |
author_role |
author |
dc.contributor.advisor1.fl_str_mv |
Goloni-Bertollo, Eny Maria |
dc.contributor.advisor1Lattes.fl_str_mv |
http://lattes.cnpq.br/9176636696202692 |
dc.contributor.referee1.fl_str_mv |
Castanhole-Nunes, Márcia Maria Urbanin |
dc.contributor.referee1Lattes.fl_str_mv |
http://lattes.cnpq.br/0665944455231316 |
dc.contributor.referee2.fl_str_mv |
Cintra, Mariangela Torreglosa Ruiz |
dc.contributor.referee2Lattes.fl_str_mv |
http://lattes.cnpq.br/5420819970399848 |
dc.contributor.authorID.fl_str_mv |
35409856899 |
dc.contributor.authorLattes.fl_str_mv |
http://lattes.cnpq.br/2023219167678846 |
dc.contributor.author.fl_str_mv |
Agren, Camila |
contributor_str_mv |
Goloni-Bertollo, Eny Maria Castanhole-Nunes, Márcia Maria Urbanin Cintra, Mariangela Torreglosa Ruiz |
dc.subject.eng.fl_str_mv |
Polymorphism, Genetic Liver Cirrhosis Carcinoma, Hepatocellular |
topic |
Polymorphism, Genetic Liver Cirrhosis Carcinoma, Hepatocellular Polimorfismo Genético Cirrose Hepática Carcinoma Hepatocelular CIENCIAS DA SAUDE::8765449414823306929::600 |
dc.subject.por.fl_str_mv |
Polimorfismo Genético Cirrose Hepática Carcinoma Hepatocelular |
dc.subject.cnpq.fl_str_mv |
CIENCIAS DA SAUDE::8765449414823306929::600 |
description |
Liver cancer ranks fifth in incidence and third in mortality worldwide. Most new cases and deaths occur in developing countries. Cirrhosis is a major risk factor for hepatocellular carcinoma (HCC). Several studies have shown that polymorphisms in cytochrome P450 (CYPs) genes can contribute to the etiology of complex diseases, as well as liver cancer. Polymorphisms in the genes of this family can alter the expression or function of the protein and influence the individual levels of detoxification, which contribute to the development of liver diseases. Objective: To investigate the association between the genetic polymorphisms CYP1A1*2A (rs4646903), CYP1A1*2C (rs1048943), CYP2E1*5B (rs2031920), CYP1E1*6 (rs6413432) and the risk of hepatic cirrhosis and HCC. Casuistic and Methods: Seven hundred and forty-five subjects (160 cirrhosis patients, 97 HCC patients and 488 controls) were evaluated. Polymorphisms were investigated by polymerase chain reaction / restriction fragment length polymorphism (PCR-RFLP) and Real-Time PCR. Statistical analyses were performed by chi-square and binary logistic regression. Survival analysis was performed using Kaplan Meier curve and Log rank test. Results: The results showed that age ≥ 60 years was associated with HCC (OR = 12.22, 95% CI: 7.17-20.82, p <0.001) and age ≥57 years was a risk factor for cirrhosis (OR = 7.12 CI 95% 4.68-10.84, p <0.001). Hepatitis B (OR = 7.84, 95% CI: 1.86-33.08, p = 0.005) and alpha fetoprotein> 500 ng / mL (OR = 3.73, 95% CI: 1.25-11, 13; p = 0.018) were associated with HCC. The polymorphisms CYP1A1 *2A, CYP1A1 *2C, CYP2E1 *5B and CYP2E1 *6 were not associated with risk of HCC and cirrhosis (p> 0.05), as well as CYP1A1 and CYP2E1 haplotypes (p > 0.05). There was no interaction between polymorphisms and smoking or alcohol consumption in the risk for HCC and cirrhosis (p> 0.05). No association was found between the polymorphisms and clinical parameters in HCC patients (p> 0.05). CYP2E1 *5B and CYP2E1 *6 polymorphisms were associated with a reduction in survival in HCC patients (p = 0.0234 and p = 0.0424, respectively). Conclusion: This study concludes that age is associated with the risk of developing HCC and cirrhosis, and CYP2E1 *5B and CYP2E1 *6 polymorphisms contribute for the reduced survival in HCC patients. |
publishDate |
2017 |
dc.date.issued.fl_str_mv |
2017-10-20 |
dc.date.accessioned.fl_str_mv |
2018-11-12T17:44:43Z |
dc.type.status.fl_str_mv |
info:eu-repo/semantics/publishedVersion |
dc.type.driver.fl_str_mv |
info:eu-repo/semantics/masterThesis |
format |
masterThesis |
status_str |
publishedVersion |
dc.identifier.citation.fl_str_mv |
Agren, Camila. Avaliação de polimorfismos dos genes CYP1A1 e CYP2E1 no risco para cirrose hepática e carcinoma hepatocelular. 2017. 107 f. Dissertação (Programa de Pós-Graduação em Ciências da Saúde) - Faculdade de Medicina de São José do Rio Preto, São José do Rio Preto. |
dc.identifier.uri.fl_str_mv |
http://bdtd.famerp.br/handle/tede/472 |
dc.identifier.doi.por.fl_str_mv |
1334 |
identifier_str_mv |
Agren, Camila. Avaliação de polimorfismos dos genes CYP1A1 e CYP2E1 no risco para cirrose hepática e carcinoma hepatocelular. 2017. 107 f. Dissertação (Programa de Pós-Graduação em Ciências da Saúde) - Faculdade de Medicina de São José do Rio Preto, São José do Rio Preto. 1334 |
url |
http://bdtd.famerp.br/handle/tede/472 |
dc.language.iso.fl_str_mv |
por |
language |
por |
dc.rights.driver.fl_str_mv |
info:eu-repo/semantics/openAccess |
eu_rights_str_mv |
openAccess |
dc.format.none.fl_str_mv |
application/pdf |
dc.publisher.none.fl_str_mv |
Faculdade de Medicina de São José do Rio Preto |
dc.publisher.program.fl_str_mv |
Programa de Pós-Graduação em Ciências da Saúde::-6954410853678806574::500 |
dc.publisher.initials.fl_str_mv |
FAMERP |
dc.publisher.country.fl_str_mv |
Brasil |
dc.publisher.department.fl_str_mv |
Faculdade 1::Departamento 1::306626487509624506::500 |
publisher.none.fl_str_mv |
Faculdade de Medicina de São José do Rio Preto |
dc.source.none.fl_str_mv |
reponame:Biblioteca Digital de Teses e Dissertações da FAMERP instname:Faculdade de Medicina de São José do Rio Preto (FAMERP) instacron:FAMERP |
instname_str |
Faculdade de Medicina de São José do Rio Preto (FAMERP) |
instacron_str |
FAMERP |
institution |
FAMERP |
reponame_str |
Biblioteca Digital de Teses e Dissertações da FAMERP |
collection |
Biblioteca Digital de Teses e Dissertações da FAMERP |
bitstream.url.fl_str_mv |
http://bdtd.famerp.br/bitstream/tede/472/1/license.txt http://bdtd.famerp.br/bitstream/tede/472/2/CamilaAgren_dissert.pdf |
bitstream.checksum.fl_str_mv |
bd3efa91386c1718a7f26a329fdcb468 b3b1d5227ab027ab3f0ff1f941091471 |
bitstream.checksumAlgorithm.fl_str_mv |
MD5 MD5 |
repository.name.fl_str_mv |
Biblioteca Digital de Teses e Dissertações da FAMERP - Faculdade de Medicina de São José do Rio Preto (FAMERP) |
repository.mail.fl_str_mv |
sbdc@famerp.br||joao.junior@famerp.br |
_version_ |
1809113653970993152 |